Patients were diagnosed according to the International CLL Workshop Criteria [14] and staged according to the modified Rai system [15]; patients were selected based on the following criteria: persistent lymphocytosis of more than 5.0 × 109/L, cell morphology according to French American British (FAB) criteria, clinical features, and atypical immunophenotype with CD19+, CD20+, CD5+, CD23+, Ig light chain (kappa and lambda) as revealed by flow cytometry. This evidence concerns the gene CD5 and B-cell chronic lymphocytic leukemia.